Furthermore, we evaluated the levels of these three miRNAs according to clinicopathological features of breast cancer and found that the serum levels of miR-9-5p were significantly higher in the HER2-positive breast cancer patients compared to the HER2-negative patients. Here, ERBB2 is linked to breast cancer.